Neonatal vaccination: Challenges and intervention strategies

Neonatology

Volumn 109, Issue 3, 2016, Pages 161-169

  Morris, Matthew C ^a   Surendran, Naveen ^a  

^a Rochester Regional Health System   (United States)

Author keywords

Neonate; Toll like receptor; Vaccine

Indexed keywords

IMMUNOLOGICAL ADJUVANT; MATERNAL ANTIBODY; TOLL LIKE RECEPTOR; VACCINE;

HUMAN; IMMUNE RESPONSE; IMMUNITY; NEWBORN; NEWBORN CARE; NEWBORN PERIOD; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; TH2 CELL; VACCINATION; ANIMAL; IMMUNOLOGY; PROCEDURES; TRENDS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANIMALS, NEWBORN; HUMANS; INFANT, NEWBORN; VACCINATION;

EID: 84954425974     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000442460     Document Type: Review

References (78)

1. Basha S, Surendran N, Pichichero M. Immune responses in neonates. Expert Rev Clin Immunol 2014; 10: 1171-1184
2. Plotkin SA. Vaccines: correlates of vaccineinduced immunity. Clin Infect Dis 2008; 47: 401-409
3. Permar SR, Klumpp SA, Mansfield KG, Kim WK, Gorgone DA, Lifton MA, Williams KC, Schmitz JE, Reimann KA, Axthelm MK, Polack FP, Griffin DE, Letvin NL. Role of CD8+lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol 2003; 77: 4396-4400
4. Permar SR, Moss WJ, Ryon JJ, Douek DC, Monze M, Griffin DE. Increased thymic output during acute measles virus infection. J Virol 2003; 77: 7872-7879
5. Slifka MK. Immunological memory to viral infection. Curr Opin Immunol 2004; 16: 443-450
6. Fletcher HA. Correlates of immune protection from tuberculosis. Curr Mol Med 2007; 7: 319-325
7. Strikas RA; Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group: Advisory committee on immunization practices recommended immunization schedules for persons aged 0 through 18 years-United States, 2015. MMWR Morb Mortal Wkly Rep 2015; 64: 93-94
8. Wood N, Siegrist CA. Neonatal immunization: where do we stand' Curr Opin Infect Dis 2011; 24: 190-195
9. Myers HI, Spracklen CN, Ryckman KK, Murray JC. A retrospective study of administration of vaccination for hepatitis B among newborn infants prior to hospital discharge at a Midwestern tertiary care center. Vaccine 2015; 33: 2316-2321
10. Cao LH, Liu ZM, Zhao PL, Sun SC, Xu DB, Shao MH, Zhang JD. Efficacy of combined hepatitis B immunoglobulin and hepatitis B vaccine in blocking father-infant transmission of hepatitis B viral infection. Genet Mol Res 2015; 14: 4651-4657
11. Fakharzadeh S, Kalanaky S, Hafizi M, Goya MM, Masoumi Z, Namaki S, Shakeri N, Abbasi M, Mahdavi M, Nazaran MH. The new nano-complex, Hep-c, improves the immunogenicity of the hepatitis B vaccine. Vaccine 2013; 31: 2591-2597
12. Lambert L, Sagfors AM, Openshaw PJ, Culley FJ. Immunity to RSV in early-life. Front Immunol 2014; 5: 466
13. Zaghouani H, Hoeman CM, Adkins B. Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells. Trends Immunol 2009; 30: 585-591
14. Locht C, Mielcarek N. New pertussis vaccination approaches: en route to protect newborns' FEMS Immunol Med Microbiol 2012; 66: 121-133
15. Guidelines for Vaccinating Pregnant Women. Atlanta, CDC, 2014. http://www.cdc.gov/vaccines/pubs/preg-guide.htm
16. Dorea JG. Breast-feeding and responses to infant vaccines: constitutional and environmental factors. Am J Perinatol 2012; 29: 759-775
17. Polewicz M, Gracia A, Garlapati S, van Kessel J, Strom S, Halperin SA, Hancock RE, Potter AA, Babiuk LA, Gerdts V. Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies. Vaccine 2013; 31: 3148-3155
18. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007; 7: 379-390
19. Belderbos ME, Levy O, Meyaard L, Bont L. Plasma-mediated immune suppression: a neonatal perspective. Pediatr Allergy Immunol 2013; 24: 102-113
20. Krumbiegel D, Zepp F, Meyer CU. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells. Hum Immunol 2007; 68: 813-822
21. Moingeon P. Adjuvants for allergy vaccines. Hum Vaccin Immunother 2012; 8: 1492-1498
22. Burt TD. Fetal regulatory T cells and peripheral immune tolerance in utero: implications for development and disease. Am J Reprod Immunol 2013; 69: 346-358
23. Michaelsson J, Mold JE, McCune JM, Nixon DF. Regulation of T cell responses in the developing human fetus. J Immunol 2006; 176: 5741-5748
24. Pichichero ME. Challenges in vaccination of neonates, infants and young children. Vaccine 2014; 32: 3886-3894
25. Basu S. Neonatal sepsis: the gut connection. Eur J Clin Microbiol Infect Dis 2015; 34: 215-222
26. Lisciandro JG, Prescott SL, Nadal-Sims MG, Devitt CJ, Richmond PC, Pomat W, Siba PM, Holt PG, Strickland DH, van den Biggelaar AH. Neonatal antigen-presenting cells are functionally more quiescent in children born under traditional compared with modern environmental conditions. J Allergy Clin Immunol 2012; 130: 1167-1174.e10
27. Power Coombs MR, Kronforst K, Levy O. Neonatal host defense against staphylococcal infections. Clin Dev Immunol 2013; 2013: 826303
28. de Brito CA, Goldoni AL, Sato MN. Immune adjuvants in early life: targeting the innate immune system to overcome impaired adaptive response. Immunotherapy 2009; 1: 883-895
29. Pyzik M, Rath T, Lencer WI, Baker K, Blumberg RS. FcRn: the architect behind the immune and nonimmune functions of IgG and albumin. J Immunol 2015; 194: 4595-4603
30. Marchant A, Goetghebuer T, Ota MO, Wolfe I, Ceesay SJ, De Groote D, Corrah T, Bennett S, Wheeler J, Huygen K, Aaby P, McAdam KP, Newport MJ. Newborns develop a Th1-Type immune response to Mycobacterium bovis Bacillus Calmette-Guerin vaccination. J Immunol 1999; 163: 2249-2255
31. Vaccine safety and availability-common ingredients in U.S. licensed vaccines. Silver Spring, US Food and Drug Administration, 2014. http://www.fda.gov/BiologicsBlood-Vaccines/SafetyAvailability/VaccineSafety/ucm187810.htm
32. Pichichero ME. Improving vaccine delivery using novel adjuvant systems. Hum Vaccin 2008; 4: 262-270
33. Heikkinen T, Young J, van Beek E, Franke H, Verstraeten T, Weil JG, Della Cioppa G. Safety of MF59-Adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol 2012; 207: 177.e1-177.e8
34. Griffiths KL, Khader SA. Novel vaccine approaches for protection against intracellular pathogens. Curr Opin Immunol 2014; 28: 58-63
35. van der Laan JW, Gould S, Tanir JY, ILSI HESI Vaccines and Adjuvants Safety Project Committee: Safety of vaccine adjuvants: focus on autoimmunity. Vaccine 2015; 33: 1507-1514
36. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009; 9: 287-293
37. Brito LA, Malyala P, O'Hagan DT. Vaccine adjuvant formulations: a pharmaceutical perspective. Semin Immunol 2013; 25: 130-145
38. Egli A, Santer D, Barakat K, Zand M, Levin A, Vollmer M, Weisser M, Khanna N, Kumar D, Tyrrell L, Houghton M, Battegay M, O'Shea D. Vaccine adjuvants-understanding molecular mechanisms to improve vaccines. Swiss Med Wkly 2014; 144: w13940
39. Cohen ND, Bourquin JR, Bordin AI, Kuskie KR, Brake CN, Weaver KB, Liu M, Felippe MJ, Kogut MH. Intramuscular administration of a synthetic CpG-oligodeoxynucleotide modulates functional responses of neutrophils of neonatal foals. PLoS One 2014; 9: e109865
40. Mastelic Gavillet B, Eberhardt CS, Auderset F, Castellino F, Seubert A, Tregoning JS, Lambert PH, de Gregorio E, Del Giudice G, Siegrist CA. MF59 mediates its B cell adjuvanticity by promoting T follicular helper cells and thus germinal center responses in adult and early life. J Immunol 2015
41. He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccin Immunother 2015; 11: 477-488
42. Sherman MP, Adamkin DH, Radmacher PG, Sherman J, Niklas V. Protective proteins in mammalian milks. NeoReviews 2012; 13: e293-e300
43. Sherman MP, Pritzl CJ, Xia C, Miller MM, Zaghouani H, Hahm B. Lactoferrin acts as an adjuvant during influenza vaccination of neonatal mice. Biochem Biophys Res Comm 2015; 467: 766-770
44. Berglund LJ, Avery DT, Ma CS, Moens L, Deenick EK, Bustamante J, Boisson-Dupuis S, Wong M, Adelstein S, Arkwright PD, Bacchetta R, Bezrodnik L, Dadi H, Roifman CM, Fulcher DA, Ziegler JB, Smart JM, Kobayashi M, Picard C, Durandy A, Cook MC, Casanova JL, Uzel G, Tangye SG. IL-21 signalling via Stat3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts. Blood 2013; 122: 3940-3950
45. Takaki H, Takeda M, Tahara M, Shingai M, Oshiumi H, Matsumoto M, Seya T. The MyD88 pathway in plasmacytoid and CD4+dendritic cells primarily triggers type I IFN production against measles virus in a mouse infection model. J Immunol 2013; 191: 4740-4747
46. Zhang X, Casartelli N, Lemoine S, Mozeleski B, Azria E, Le Ray C, Schwartz O, Launay O, Leclerc C, Lo-Man R. Plasmacytoid dendritic cells engagement by influenza vaccine as a surrogate strategy for driving T-helper type 1 responses in human neonatal settings. J Infect Dis 2014; 210: 424-434
47. Schmitt N, Bustamante J, Bourdery L, Bentebibel SE, Boisson-Dupuis S, Hamlin F, Tran MV, Blankenship D, Pascual V, Savino DA, Banchereau J, Casanova J-L, Ueno H. IL-12 receptor β1 deficiency alters in vivo T follicular helper cell response in humans. Blood 2013; 121: 3375-3385
48. Ma CS, Suryani S, Avery DT, Chan A, Nanan R, Santner-Nanan B, Deenick EK, Tangye SG. Early commitment of naive human CD4(+) T cells to the T follicular helper (T(FH)) cell lineage is induced by IL-12. Immunol Cell Biol 2009; 87: 590-600
49. Palucka K, Banchereau J. Human dendritic cell subsets in vaccination. Curr Opin Immunol 2013; 25: 396-402
50. Cohn L, Delamarre L. Dendritic cell-Targeted vaccines. Front Immunol 2014; 5: 255
51. Morris MC, Gilliam EA, Li L. Innate immune programing by endotoxin and its pathological consequences. Front Immunol 2014; 5: 680
52. Akira S. Innate immunity and adjuvants. Philos Trans R Soc Lond B Biol Sci 2011; 366: 2748-2755
53. Xi CX, Xiong F, Zhou Z, Mei L, Xiong WC. Pyk2 interacts with MyD88 and regulates MyD88-mediated NF-kappaB activation in macrophages. J Leukoc Biol 2010; 87: 415-423
54. Wu M, Wang H, Shi J, Sun J, Duan Z, Li Y, Li J, Hu N, Wei Y, Chen Y, Hu Y. Gene expression profiles identify both MyD88-independent and MyD88-dependent pathways involved in the maturation of dendritic cells mediated by heparan sulfate: a novel adjuvant. Hum Vaccin Immunother 2014; 10: 3711-3721
55. Maisonneuve C, Bertholet S, Philpott DJ, De Gregorio E. Unleashing the potential of NOD-And Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci USA 2014; 111: 12294-12299
56. Philbin VJ, Dowling DJ, Gallington LC, Cortes G, Tan Z, Suter EE, Chi KW, Shuckett A, Stoler-Barak L, Tomai M, Miller RL, Mansfield K, Levy O. Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways. J Allergy Clin Immunol 2012; 130: 195-204.e199
57. Norton EB, Bauer DL, Weldon WC, Oberste MS, Lawson LB, Clements JD. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. Vaccine 2015; 33: 1909-1915
58. Perez O, Romeu B, Cabrera O, Gonzalez E, Batista-Duharte A, Labrada A, Perez R, Reyes LM, Ramirez W, Sifontes S, Fernandez N, Lastre M. Adjuvants are key factors for the development of future vaccines: lessons from the Finlay Adjuvant Platform. Front Immunol 2013; 4: 407
59. Aryan Z, Holgate ST, Radzioch D, Rezaei N. A new era of targeting the ancient gatekeepers of the immune system: Toll-like agonists in the treatment of allergic rhinitis and asthma. Int Arch Allergy Immunol 2014; 164: 46-63
60. Raby AC, Holst B, Le Bouder E, Diaz C, Ferran E, Conraux L, Guillemot JC, Coles B, Kift-Morgan A, Colmont CS, Szakmany T, Ferrara P, Hall JE, Topley N, Labeta MO. Targeting the TLR co-receptor CD14 with TLR2-derived peptides modulates immune responses to pathogens. Sci Transl Med 2013; 5: 185ra164
61. Kwak MS, Lim M, Lee YJ, Lee HS, Kim YH, Youn JH, Choi JE, Shin JS. HMGB1 binds to lipoteichoic acid and enhances TNF-α and IL-6 production through HMGB1-mediated transfer of lipoteichoic acid to CD14 and TLR2. J Innate Immun 2015; 7: 405-416
62. Futata EA, Fusaro AE, de Brito CA, Sato MN. The neonatal immune system: Immunomodulation of infections in early life. Expert Rev Anti Infect Ther 2012; 10: 289-298
63. Carty M, Goodbody R, Schroder M, Stack J, Moynagh PN, Bowie AG. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat Immunol 2006; 7: 1074-1081
64. Cuenca AG, Joiner DN, Gentile LF, Cuenca AL, Wynn JL, Kelly-Scumpia KM, Scumpia PO, Behrns KE, Efron PA, Nacionales D, Lui C, Wallet SM, Reeves WH, Mathews CE, Moldawer LL. TRIF-dependent innate immune activation is critical for survival to neonatal Gram-negative sepsis. J Immunol 2015; 194: 1169-1177
65. Saito Y, Yanagawa Y, Kikuchi K, Iijima N, Iwabuchi K, Onoe K. Low-dose lipopolysaccharide modifies the production of IL-12 by dendritic cells in response to various cytokines. J Clin Exp Hematop 2006; 46: 31-36
66. Schmitt N, Ueno H. Regulation of human helper T cell subset differentiation by cytokines. Curr Opin Immunol 2015; 34: 130-136
67. Cuenca AG, Wynn JL, Moldawer LL, Levy O. Role of innate immunity in neonatal infection. Am J Perinatol 2013; 30: 105-112
68. Morris MC, Gilliam EA, Button J, Li L. Dynamic modulation of innate immune response by varying dosages of lipopolysaccharide (LPS) in human monocytic cells. J Biol Chem 2014; 289: 21584-21590
69. Ferrante CJ, Pinhal-Enfield G, Elson G, Cronstein BN, Hasko G, Outram S, Leibovich SJ. The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Ralpha) signaling. Inflammation 2013; 36: 921-931
70. Pernet E, Brunet J, Guillemot L, Chignard M, Touqui L, Wu Y. Staphylococcus aureus adenosine inhibits sPLA2-IIA-mediated host killing in the airways. J Immunol 2015; 194: 5312-5319
71. De Wit D, Olislagers V, Goriely S, Vermeulen F, Wagner H, Goldman M, Willems F. Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. Blood 2004; 103: 1030-1032
72. Goriely S, Goldman M. From tolerance to autoimmunity: is there a risk in early life vaccination' J Comp Pathol 2007; 137(suppl 1): S57-S61
73. Fischer H, Ellstrom P, Ekstrom K, Gustafsson L, Gustafsson M, Svanborg C. Ceramide as a TLR4 agonist; a putative signalling intermediate between sphingolipid receptors for microbial ligands and TLR4. Cell Microbiol 2007; 9: 1239-1251
74. Chen Q, Ross AC. Alpha-galactosylceramide stimulates splenic lymphocyte proliferation in vitro and increases antibody production in vivo in late neonatal-Age mice. Clin Exp Immunol 2015; 179: 188-196
75. Ma Y, Ross AC. The anti-Tetanus immune response of neonatal mice is augmented by retinoic acid combined with polyriboinosinic: polyribocytidylic acid. Proc Natl Acad Sci USA 2005; 102: 13556-13561
76. Gracia A, Polewicz M, Halperin SA, Hancock RE, Potter AA, Babiuk LA, Gerdts V. Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations. Vaccine 2011; 29: 1595-1604
77. Corbett NP, Blimkie D, Ho KC, Cai B, Sutherland DP, Kallos A, Crabtree J, Rein-Weston A, Lavoie PM, Turvey SE, Hawkins NR, Self SG, Wilson CB, Hajjar AM, Fortuno ES 3rd, Kollmann TR. Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS One 2010; 5: e15041
78. Dowling DJ, Tan Z, Prokopowicz ZM, Palmer CD, Matthews MA, Dietsch GN, Hershberg RM, Levy O. The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes. PLoS One 2013; 8: e58164